TLR5 opens the door to neuropathic-pain treatment
Opening the door to an epigenetic target
Closing the door on KRAS-mutant lung cancer
Opening the door to TB
Basigin opens the door to malaria
In and out through the same cohesin door
JAK — opening the door to acquired resistance
PD-1 blockade: opening the door to attack
As one door closes, another opens